Added to YB: 2025-11-12
Pitch date: 2025-11-08
NVO [bullish]
Novo Nordisk A/S
+2.9%
current return
Author Info
Summit Stocks shares weekly in-depth articles on the best stocks and insights into their portfolio. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.4T
Pitch Price
DKK 298.75
Price Target
N/A
Dividend
3.76%
EV/EBITDA
9.60
P/E
13.52
EV/Sales
4.81
Sector
Pharmaceuticals
Category
turnaround
Novo Nordisk: Expectations Can't Get Lower
NVO: New CEO Doustdar refocusing on DTC expansion & oral Wegovy launch early 2026. Q3 rev +5% YoY to 75B DKK but growth stagnating vs Lilly. Lowered 2025 guidance to 8-11% rev growth. Trading 70% off highs at 11.9% FCF yield. Needs only 8% annual FCF growth to justify current price.
Read full article (6 min)